641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipili...
641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma
About this item
Full title
Author / Creator
Baretti, Marina , Ladle, Brian , Nauroth, Julie , Wang, Hao , Durham, Jennifer , Thoburn, Christopher , Ferguson, Anna , Thompson, Alex , Brancati, Madalena , Griffith, Paige , Kamdar, Zeal , Kirk, Allison , Zaidi, Neeha , Huff, Amanda , Ho, Won , Furth, Mark , Thomas, Paul , Jaffee, Elizabeth M and Yarchoan, Mark
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundFibrolamellar carcinoma (FLC) is a form of liver cancer primarily affecting children and young adults. The signature genomic event is a chimeric transcript between DNAJB1 and PRKACA. Direct targeting of the fusion has been unsuccessful due to unacceptable on-target toxicities. The DNAJB1-PRKACA fusion breakpoint occurs in an intron, creat...
Alternative Titles
Full title
641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3daf0dc0473d405e8cfc4646bd654963
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3daf0dc0473d405e8cfc4646bd654963
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0641
